2-methyl-1,3-propanediamine hydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-methyl-1,3-propanediamine hydrochloride
• 英文别名: 2-methyl-1,3-propandiamine hydrochloride；2-methylpropane-1,3-diamine;hydrochloride
• 化学式: C₄H₁₂N₂*ClH
• 分子量: 124.614
• InChiKey: ZFMVWTHVXNBHNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.04
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ammonium platinum(II) chloride 、 2-methyl-1,3-propanediamine hydrochloride 以 sodium hydroxide 为溶剂， 生成 {PtmtnCl2}
  参考文献：
  名称：

  Mann, F. G., Journal of the Chemical Society

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 作用下， 生成 2-methyl-1,3-propanediamine hydrochloride
  参考文献：
  名称：

  Mann, Journal of the Chemical Society, 1927, p. 2912

  摘要：

  DOI：

文献信息

• Controlling the Electronic States and Physical Properties of MMX-Type Diplatinum-Iodide Chain Complexes via Binary Countercations
  作者：Hiroaki Iguchi、Shinya Takaishi、Brian K. Breedlove、Masahiro Yamashita、Hiroyuki Matsuzaki、Hiroshi Okamoto

  DOI：10.1021/ic301469u

  日期：2012.9.17

  MMX-type quasi-one-dimensional iodide-bridged dinuclear Pt complexes (MMX chains) with binary countercations show a new alternating charge-polarization + charge-density-wave (ACP+CDW) electronic state and reversible switching of the electronic states and physical properties upon dehydration and rehydration process. By comparing several MMX chains with various binary countercations with previous chains

  具有二元抗衡离子的MMX型准一维碘桥双核Pt络合物（MMX链）显示出新的交替电荷极化+电荷密度波（ACP + CDW）电子状态以及电子状态和物理状态的可逆转换脱水和再水化过程中的特性。通过将几个具有不同二元抗衡阳离子的MMX链与先前的链进行比较，我们发现脂族二铵离子的短骨架对于实现ACP + CDW状态是必不可少的，因为它通过配体的扭曲沿链轴诱导了2倍的周期性。而且，脱水和再水化时结构和电导率变化的可逆性取决于脂族二铵离子的长度。短的二铵离子支持稳健的框架，经历了可逆的结构变化。另一方面，长且弯曲的脂族二铵离子削弱了骨架，当结构改变时，这会导致晶体的部分降解和电导率的降低。然而，在脱水过程之后，电导率的活化能的降低与络合物的坚固性无关，这表明在脱水时，带有二元抗衡阳离子的MMX链中的轨道重叠增加。可控的电子状态和物理特性为基于MMX链设计多功能材料提供了一个平台。当结构改变时，这会导致晶体
• Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1295885A1

  公开（公告）日：2003-03-26

  The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a hydroxyiminomethylene group, a dioxolan group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C3-6 cycloalkyl group, a C1-4 alkyl group, a C1-4 alkoxy group, a benzyl group or a halogen atom;    when Y represents a bond, a methylene group optionally substituted , a hydroxyiminomethylene group, a dioxolan group or a carbonyl group then R2 represents a C1-6 alkyl group optionally; a C3-6 cycloalkyl group, a C1-4 alkylthio group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a phenyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a pyridyl ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ;    when Y represents a ethenylene group, a ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C1-6 alkyl group optionally substituted by a hydroxy group, a C6,10 aryloxy or a C6,10 arylamino group; a C3-6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a benzyl group, a phenyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a C6,10 arylamino, a pyridyl ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ; R3 and R4 represents, each independently, a hydrogen atom, a C1-6 alkyl group, a hydroxy group, a C1-4 alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; with the proviso that when R3 and R4 represent each a hydrogen atom then R5 is not a hydrogen atom; The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.

  该发明涉及一种由式（I）表示的吡啶酮衍生物或其盐，其中：X代表两个氢原子、一个硫原子、一个氧原子或一个C1-2烷基和一个氢原子；Y代表一个键、一个乙烯基团、一个乙炔基团、一个氧原子、一个硫原子、一个磺酰基、一个亚砜基、一个羰基、一个羟亚胺亚甲基基团、一个二氧杜乐烷基团、一个氮原子（可选择地取代）；或一个（可选择地取代的）亚甲基基团；R1代表一个2、3或4-吡啶基团，可选择地取代为一个C3-6环烷基团、一个C1-4烷基团、一个C1-4烷氧基团、一个苄基或一个卤原子；当Y代表一个键、一个（可选择地取代的）亚甲基基团、一个羟亚胺亚甲基基团、一个二氧杜乐烷基团或一个羰基时，R2代表一个（可选择地）C1-6烷基团；一个C3-6环烷基团、一个C1-4硫代烷基团、一个C1-4烷氧基团、一个C1-2全氟烷基团、一个C1-3卤代烷基团、一个苯硫基团、一个苄基、一个苯环、一个5,6,7,8-四氢萘基环、一个萘基环、一个吡啶基环、一个吡咯基环、一个噻吩基环、一个呋喃基环或一个咪唑基环；当Y代表一个乙烯基团、一个乙炔基团、一个氧原子、一个硫原子、一个磺酰基、一个亚砜基或一个（可选择地取代的）氮原子时，R2代表一个（可选择地取代的）C1-6烷基团，可选择地取代为一个羟基、一个C6,10芳氧基或一个C6,10芳基氨基；一个C3-6环烷基团、一个C1-2全氟烷基团、一个C1-3卤代烷基团、一个苄基、一个苯环、一个5,6,7,8-四氢萘基环、一个萘基环、一个C6,10芳基氨基、一个吡啶基环、一个吡咯基环、一个噻吩基环、一个呋喃基环或一个咪唑基环；R3和R4分别独立地代表一个氢原子、一个C1-6烷基团、一个羟基、一个C1-4烷氧基团或一个卤原子；R5代表一个氢原子、一个C1-6烷基团或一个卤原子；但是如果R3和R4分别代表一个氢原子，则R5不是一个氢原子；该发明还涉及一种药物，包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β或GSK3β和cdk5/p25异常活性引起的神经退行性疾病，如阿尔茨海默病。
• Heteroaryl substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1340758A1

  公开（公告）日：2003-09-03

  The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring optionally substituted; R2 represents a heterocyclic bicyclic rings, having 1-4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom and having 5-9 carbon atoms, of formula R3 represents a hydrogen atom, a C1-6 alkyl group, a hydroxy group, a C1-4 alkoxy group or a halogen atom; R4 represents a hydrogen atom, a C1-6 alkyl group, a C1-4 alkoxy group or a halogen atom; The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.

  本发明涉及一种由公式（I）表示的嘧啶酮衍生物或其盐，其中：X代表两个氢原子，一个硫原子，一个氧原子或一个C1-2烷基基团和一个氢原子；Y代表键，乙烯基团，乙炔基团或者一个可选取代的亚甲基基团；R1代表一个可选取代的2,3或4-吡啶环；R2代表一个杂环双环环，具有1-4个从氧原子、硫原子和氮原子中选取的杂原子和5-9个碳原子，其化学式为；R3代表一个氢原子，一个C1-6烷基基团，一个羟基，一个C1-4烷氧基或者一个卤素原子；R4代表一个氢原子，一个C1-6烷基基团，一个C1-4烷氧基或者一个卤素原子。本发明还涉及一种药物，其中包括所述衍生物或其盐作为活性成分，可用于预防和/或治疗由GSK3β或GSK3β和cdk5/p25的异常活性引起的神经退行性疾病，例如阿尔茨海默病。
• Synthesis, characterization and structure of cis and trans cobalt(III) bis chelates of 2-methyl-1,3-propanediamine, a prochiral sinambic ligand
  作者：J.Douglas Mather、Robert E. Tapscott、Charles F. Campana

  DOI：10.1016/s0020-1693(00)90857-0

  日期：1983.1

  Abstract Cis and trans isomers of [Co(metn)2Cl2]+ (metn = 2-methyl-1,3-propanediamine) have been prepared and characterized. Owing to the presence of rotationally nonequivalent donor atoms in the prochiral ligand, three diastereomers are possible for the cis isomer (C2(anti), C2(syn), and C1) and two diastereomers are possible for the trans complex (C2h and C2ν). A crystal structure of the purple compound

  摘要制备并表征了[Co（metn）2Cl2] +（metn = 2-methyl-1,3-propanediamine）的顺式和反式异构体。由于前手性配体中存在旋转不等价的供体原子，顺式异构体可能为三个非对映异构体（C2（反），C2（syn）和C1），反式复合物可能为两个非对映异构体（C2h和C2ν） 。紫色化合物[Co（metn）2Cl2] Cl·1 4 CH3OH的晶体结构显示同时存在顺式C2（反）和反式C2h异构体。对绿色[Co（metn）2Cl2]（H3O）Cl2·H2O的结构未完成确定，仅揭示了反式C2h异构体。X射线晶体学也显示与1，3-丙二胺相比，6元元甲基螯合环变平。尽管反式-[Co（metn）2Cl2] +的13C NMR光谱显示溶液中不存在一种以上异构体的证据，这可能是由于两种非对映异构体之间的化学位移差异很小而无法检测到的。红外光谱表明在KBr存在下固态[Co（metn）2Cl2]
• Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives
  申请人：Gallet Thierry

  公开号：US20050049261A1

  公开（公告）日：2005-03-03

  The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a hydroxyiminomethylene group, a dioxolan group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring optionally substituted; R2 may represent a C 1-6 alkyl group optionally; a C 3-6 cycloalkyl group, a C 1-4 alkythio group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; R3 and R4 represent, each independently, a hydrogen atom, a C 1-6 alkyl group, a hydroxy group, a C 1-4 alkoxy group or a halogen atom; R5 represents a hydrogen atom, a C 1-6 alkyl group or a halogen atom; with the proviso that when R3 and R4 represent each a hydrogen atom then R5 is not a hydrogen atom. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β, and cdk5/p25, such as Alzheimer disease.

  本发明涉及一种由式(I)表示的嘧啶酮衍生物或其盐，其中X代表两个氢原子，硫原子，氧原子或C1-2烷基基团和一个氢原子；Y代表键，乙烯基团，乙炔基团，氧原子，硫原子，磺酰基，亚磺酸基，羰基，羟亚胺亚甲基基团，二氧杂环己烷基团，氮原子可选地取代；或取代的亚甲基基团；R1表示可选地取代的2、3或4-吡啶环；R2可以表示可选的C1-6烷基基团；C3-6环烷基团，C1-4烷硫基团，C1-4烷氧基团，C1-2全氟烷基团，C1-3卤代烷基团，苯硫基团，苯甲基基团，苯环，茚环，5,6,7,8-四氢萘环，萘环，吡啶环，吡咯环，噻吩环，呋喃环或咪唑环；R3和R4分别表示氢原子，C1-6烷基基团，羟基，C1-4烷氧基团或卤素原子；R5表示氢原子，C1-6烷基基团或卤素原子；但是当R3和R4分别表示氢原子时，R5不是氢原子。本发明还涉及一种药物，其包含所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β或GSK3β和cdk5/p25的异常活动引起的神经退行性疾病，如阿尔茨海默病。